Mizuho Securities Sticks to Its Buy Rating for Akebia Therapeutics

By Carrie Williams

Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $24. The company’s shares closed yesterday at $13.52.

According to TipRanks.com, Yang is a 5-star analyst with an average return of 23.8% and a 53.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Nightstar Therapeutics Limited, and Fennec Pharmaceuticals Inc.

Akebia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $24.

The company has a one-year high of $20.25 and a one-year low of $8.69. Currently, Akebia Therapeutics has an average volume of 316.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor and biology. It also includes the development and commercialization of drugs for the treatment of renal and metabolic disorders.